Germline Cancer-Predisposition Variants in Pediatric Rhabdomyosarcoma: A Report from the Children's Oncology Group.

TitleGermline Cancer-Predisposition Variants in Pediatric Rhabdomyosarcoma: A Report from the Children's Oncology Group.
Publication TypeJournal Article
Year of Publication2020
AuthorsLi, H, Sisoudiya, SD, Martin-Giacalone, BA, Khayat, MM, Dugan-Perez, S, Marquez-Do, DA, Scheurer, ME, Muzny, DM, Boerwinkle, E, Gibbs, RA, Chi, Y-Y, Barkauskas, DA, Lo, T, Hall, D, Stewart, DR, Schiffman, JD, Skapek, SX, Hawkins, DS, Plon, SE, Sabo, A, Lupo, PJ
JournalJ Natl Cancer Inst
Date Published2020 Dec 29
ISSN1460-2105
Abstract

BACKGROUND: Several cancer-susceptibility syndromes are reported to underlie pediatric rhabdomyosarcoma (RMS); however, there have been no systematic efforts to characterize the heterogeneous genetic etiologies of this often-fatal malignancy.

METHODS: We performed exome-sequencing on germline DNA from 615 patients with newly diagnosed RMS consented through the Children's Oncology Group. We compared the prevalence of cancer-predisposition variants in 63 autosomal dominant cancer-predisposition genes in these patients with population controls (n = 9,963). All statistical tests were two-sided.

RESULTS: We identified germline cancer-predisposition variants in 45 RMS patients (7.3%; all FOXO1 fusion-negative) across 15 autosomal dominant genes, which was statistically significantly enriched compared with controls (1.4%; p = 1.3 × 10-22). Specifically, 73.3% of the predisposition variants were found in predisposition syndrome genes previously associated with pediatric RMS risk, such as Li-Fraumeni syndrome (TP53) and neurofibromatosis type I (NF1). Notably, five patients had well-described oncogenic missense variants in HRAS (p.G12V and p. G12S) associated with Costello syndrome. Also, genetic etiology differed with histology, as germline variants were more frequent in embryonal versus alveolar RMS patients (10.0% vs. 3.0%, p = .02). While patients with a cancer-predisposition variant tended to be younger at diagnosis (p = 9.9 × 10-4), 40.0% of germline variants were identified in those >3 years of age, which is in contrast to current genetic testing recommendations based on early age at diagnosis.

CONCLUSIONS: These findings demonstrate that genetic risk of RMS results from germline predisposition variants associated with a wide spectrum of cancer-susceptibility syndromes. Germline genetic testing for children with RMS should be informed by RMS subtypes and not be limited to only young patients.

DOI10.1093/jnci/djaa204
Alternate JournalJ Natl Cancer Inst
PubMed ID33372952
Grant ListU10 CA180899 / CA / NCI NIH HHS / United States